The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Open accessAbstract
Aberrancy in cell cycle progression is one of the fundamental mechanisms underlying tumorigenesis, making regulators of the cell cycle machinery rational anti-cancer therapeutic targets. Growing body of evidence indicates that the cell cycle regulatory pathway integrates into other hallmarks of cancer, including metabolism remodeling and immune escaping. Thus, therapies against cell cycle machinery components can not only repress the division of cancer cells, but also reverse cancer metabolism and restore cancer immune surveillance. Apart from the ongoing effects on developing small molecule inhibitors (SMIs) of cell cycle machinery, PROTACs have recently been used for targeting these oncogenic proteins related to cell cycle progression. Here, we discuss the rationale of cell cycle targeting therapies, particularly PROTACs, to more efficiently retard tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Control of cell cycle transcription during G1 and S phases
Bertoli, C., Skotheim, J. M., & de Bruin, R. A. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3629 · Cited by 1,500
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Peng, J., Sun, B.-F., Chen, C.-Y., Zhou, J.-Y., Chen, Y.-S., Chen, H., Liu, L., Huang, D., Jiang, J., Cui, G.-S., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0195-y · Cited by 1,321
The anaphase promoting complex/cyclosome: a machine designed to destroy
Peters, J.-M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1988 · Cited by 1,315
Metabolic regulation of cell growth and proliferation
Zhu, J., & Thompson, C. B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0123-5 · Cited by 1,116
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Self-citationLogic of the Yeast Metabolic Cycle: Temporal Compartmentalization of Cellular Processes
Tu, B. P., Kudlicki, A., Rowicka, M., & McKnight, S. L. (2005) · Science · doi:10.1126/science.1120499 · Cited by 901
Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer
Frescas, D., & Pagano, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2396 · Cited by 890
Herrero-Mendez, A., Almeida, A., Fernández, E., Maestre, C., Moncada, S., & Bolaños, J. P. (2009) · Nature Cell Biology · doi:10.1038/ncb1881 · Cited by 844
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 800
The Spindle Assembly Checkpoint
Lara-Gonzalez, P., Westhorpe, F. G., & Taylor, S. S. (2012) · Current Biology · doi:10.1016/j.cub.2012.10.006 · Cited by 773
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750
GENETIC CONTROL OF THE CELL DIVISION CYCLE IN YEAST: V. GENETIC ANALYSIS OF cdc MUTANTS
Hartwell, L. H., Mortimer, R. K., Culotti, J., & Culotti, M. (1973) · Genetics · doi:10.1093/genetics/74.2.267 · Cited by 740
Mechanisms and function of substrate recruitment by F-box proteins
Skaar, J. R., Pagan, J. K., & Pagano, M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3582 · Cited by 689
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620
A Long Twentieth Century of the Cell Cycle and Beyond
Nurse, P. (2000) · Cell · doi:10.1016/s0092-8674(00)81684-0 · Cited by 618
Roles of F-box proteins in cancer
Wang, Z., Liu, P., Inuzuka, H., & Wei, W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3700 · Cited by 523
Self-citationLoss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.006 · Cited by 508
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 501
Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469
Chan, C.-H., Li, C.-F., Yang, W.-L., Gao, Y., Lee, S.-W., Feng, Z., Huang, H.-Y., Tsai, K. K. C., Flores, L. G., Shao, Y., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.065 · Cited by 437
Self-citationThe CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
Ruscetti, M., Morris, J. P., Mezzadra, R., Russell, J., Leibold, J., Romesser, P. B., Simon, J., Kulick, A., Ho, Y.-J., Fennell, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.008 · Cited by 424
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science · doi:10.1126/science.aas9090 · Cited by 415
Condorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
The G2-phase DNA-damage checkpoint
O’Connell, M. J., Walworth, N. C., & Carr, A. M. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01773-6 · Cited by 384
Cyclin B1/Cdk1 Coordinates Mitochondrial Respiration for Cell-Cycle G2/M Progression
Wang, Z., Fan, M., Candas, D., Zhang, T.-Q., Qin, L., Eldridge, A., Wachsmann-Hogiu, S., Ahmed, K. M., Chromy, B. A., Nantajit, D., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.03.012 · Cited by 380
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Rational discovery of molecular glue degraders via scalable chemical profiling
Mayor-Ruiz, C., Bauer, S., Brand, M., Kozicka, Z., Siklos, M., Imrichova, H., Kaltheuner, I. H., Hahn, E., Seiler, K., Koren, A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0594-x · Cited by 369
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
Liu, P., Begley, M., Michowski, W., Inuzuka, H., Ginzberg, M., Gao, D., Tsou, P., Gan, W., Papa, A., Kim, B. M., et al. (2014) · Nature · doi:10.1038/nature13079 · Cited by 361
Self-citationCDK Substrate Phosphorylation and Ordering the Cell Cycle
Swaffer, M. P., Jones, A. W., Flynn, H. R., Snijders, A. P., & Nurse, P. (2016) · Cell · doi:10.1016/j.cell.2016.11.034 · Cited by 349
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347
Targeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.001 · Cited by 333
The concept of immune surveillance against tumors: The first theories
Ribatti, D. (2017) · Oncotarget · doi:10.18632/oncotarget.12739 · Cited by 332
PHOTACs enable optical control of protein degradation
Reynders, M., Matsuura, B. S., Bérouti, M., Simoneschi, D., Marzio, A., Pagano, M., & Trauner, D. (2020) · Science Advances · doi:10.1126/sciadv.aay5064 · Cited by 321
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313
Cancer Selective Target Degradation by Folate-Caged PROTACs
Liu, J., Chen, H., Liu, Y., Shen, Y., Meng, F., Kaniskan, H. Ü., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00451 · Cited by 297
Self-citationAddressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08008 · Cited by 293
Light-induced control of protein destruction by opto-PROTAC
Liu, J., Chen, H., Ma, L., He, Z., Wang, D., Liu, Y., Lin, Q., Zhang, T., Gray, N., Kaniskan, H. Ü., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay5154 · Cited by 292
Self-citationDevelopment of dual and selective degraders of cyclin-dependent kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Costa, C., Wang, Y., Ly, A., Hosono, Y., Murchie, E., Walmsley, C. S., Huynh, T., Healy, C., Peterson, R., Yanase, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0830 · Cited by 270
Gao, D., Inuzuka, H., Tseng, A., Chin, R. Y., Toker, A., & Wei, W. (2009) · Nature Cell Biology · doi:10.1038/ncb1847 · Cited by 267
Self-citationCDK6 as a key regulator of hematopoietic and leukemic stem cell activation
Scheicher, R., Hoelbl-Kovacic, A., Bellutti, F., Tigan, A.-S., Prchal-Murphy, M., Heller, G., Schneckenleithner, C., Salazar-Roa, M., Zöchbauer-Müller, S., Zuber, J., et al. (2015) · Blood · doi:10.1182/blood-2014-06-584417 · Cited by 262
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Brand, M., Jiang, B., Bauer, S., Donovan, K. A., Liang, Y., Wang, E. S., Nowak, R. P., Yuan, J. C., Zhang, T., Kwiatkowski, N., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.006 · Cited by 258
Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
Sackton, K. L., Dimova, N., Zeng, X., Tian, W., Zhang, M., Sackton, T. B., Meaders, J., Pfaff, K. L., Sigoillot, F., Yu, H., et al. (2014) · Nature · doi:10.1038/nature13660 · Cited by 257
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 257
TF-PROTACs Enable Targeted Degradation of Transcription Factors
Liu, J., Chen, H., Kaniskan, H. Ü., Xie, L., Chen, X., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03852 · Cited by 247
Self-citationTripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247
Yalcin, A., Clem, B. F., Simmons, A., Lane, A., Nelson, K., Clem, A. L., Brock, E., Siow, D., Wattenberg, B., Telang, S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.016816 · Cited by 242
Chen, Z., Odstrcil, E. A., Tu, B. P., & McKnight, S. L. (2007) · Science · doi:10.1126/science.1140958 · Cited by 233
Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.003 · Cited by 220
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Robb, C. M., Contreras, J. I., Kour, S., Taylor, M. A., Abid, M., Sonawane, Y. A., Zahid, M., Murry, D. J., Natarajan, A., & Rana, S. (2017) · Chemical Communications · doi:10.1039/c7cc03879h · Cited by 211
Wang, C., Li, Z., Lu, Y., Du, R., Katiyar, S., Yang, J., Fu, M., Leader, J. E., Quong, A., Novikoff, P. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603363103 · Cited by 208
Emerging New Concepts of Degrader Technologies
Ding, Y., Fei, Y., & Lu, B. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.005 · Cited by 204
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
Su, S., Yang, Z., Gao, H., Yang, H., Zhu, S., An, Z., Wang, J., Li, Q., Chandarlapaty, S., Deng, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00871 · Cited by 199
Spatiotemporal dissection of the cell cycle with single-cell proteogenomics
Mahdessian, D., Cesnik, A. J., Gnann, C., Danielsson, F., Stenström, L., Arif, M., Zhang, C., Le, T., Johansson, F., Schutten, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03232-9 · Cited by 198
Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain
Verma, R., Peters, N. R., D'Onofrio, M., Tochtrop, G. P., Sakamoto, K. M., Varadan, R., Zhang, M., Coffino, P., Fushman, D., Deshaies, R. J., et al. (2004) · Science · doi:10.1126/science.1100946 · Cited by 193
PROTACs: A novel strategy for cancer therapy
Liu, J., Ma, J., Liu, Y., Xia, J., Li, Y., Wang, Z. P., & Wei, W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.006 · Cited by 186
Self-citationPhase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
Liu, J. F., Xiong, N., Campos, S. M., Wright, A. A., Krasner, C., Schumer, S., Horowitz, N., Veneris, J., Tayob, N., Morrissey, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03167 · Cited by 184
Self-citationLessard, F., Igelmann, S., Trahan, C., Huot, G., Saint-Germain, E., Mignacca, L., Del Toro, N., Lopes-Paciencia, S., Le Calvé, B., Montero, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0127-y · Cited by 174
Colombo, S. L., Palacios-Callender, M., Frakich, N., Carcamo, S., Kovacs, I., Tudzarova, S., & Moncada, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117500108 · Cited by 172
CRL4AMBRA1 is a master regulator of D-type cyclins
Simoneschi, D., Rona, G., Zhou, N., Jeong, Y.-T., Jiang, S., Milletti, G., Arbini, A. A., O’Sullivan, A., Wang, A. A., Nithikasem, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03445-y · Cited by 172
PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
Adhikari, B., Bozilovic, J., Diebold, M., Schwarz, J. D., Hofstetter, J., Schröder, M., Wanior, M., Narain, A., Vogt, M., Dudvarski Stankovic, N., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-00652-y · Cited by 171
Wood, D. J., Korolchuk, S., Tatum, N. J., Wang, L.-Z., Endicott, J. A., Noble, M. E. M., & Martin, M. P. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.015 · Cited by 168
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
Wang, L., Shao, X., Zhong, T., Wu, Y., Xu, A., Sun, X., Gao, H., Liu, Y., Lan, T., Tong, Y., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00742-5 · Cited by 168
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D
Chaikovsky, A. C., Li, C., Jeng, E. E., Loebell, S., Lee, M. C., Murray, C. W., Cheng, R., Demeter, J., Swaney, D. L., Chen, S.-H., et al. (2021) · Nature · doi:10.1038/s41586-021-03474-7 · Cited by 167
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity
Maiani, E., Milletti, G., Nazio, F., Holdgaard, S. G., Bartkova, J., Rizza, S., Cianfanelli, V., Lorente, M., Simoneschi, D., Di Marco, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03422-5 · Cited by 160
New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy
Bury, M., Calvé, B. L., Ferbeyre, G., Blank, V., & Lessard, F. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.01.010 · Cited by 144
Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity
Bian, J., Ren, J., Li, Y., Wang, J., Xu, X., Feng, Y., Tang, H., Wang, Y., & Li, Z. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.08.028 · Cited by 140
Colombo, S. L., Palacios‐Callender, M., Frakich, N., de León, J., Schmitt, C. A., Boorn, L., Davis, N., & Moncada, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012362107 · Cited by 139
Selective degradation of CDK6 by a palbociclib based PROTAC
Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135
Wang, Y., Zhi, Y., Jin, Q., Lü, S., Lin, G., Yuan, H., Yang, T., Wang, Z., Yao, C., Ling, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01261 · Cited by 132
PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer
Zhao, B., & Burgess, K. (2019) · Chemical Communications · doi:10.1039/c9cc00163h · Cited by 131
Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle
Liu, J., Peng, Y., Shi, L., Wan, L., Inuzuka, H., Long, J., Guo, J., Zhang, J., Yuan, M., Zhang, S., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0372-z · Cited by 124
Self-citationDevelopment of selective mono or dual PROTAC degrader probe of CDK isoforms
Zhou, F., Chen, L., Cao, C.-G., Yu, J., Luo, X., Zhou, P., Zhao, L., Du, W., Cheng, J., Xie, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111952 · Cited by 121
Stabilizers and Destabilizers Controlling Cell Cycle Oscillators
Guardavaccaro, D., & Pagano, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.017 · Cited by 118
Fujimoto, T., Anderson, K., Jacobsen, S. E. W., Nishikawa, S.-I., & Nerlov, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601675 · Cited by 113
Chen, J., Harding, S. M., Natesan, R., Tian, L., Benci, J. L., Li, W., Minn, A. J., Asangani, I. A., & Greenberg, R. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108080 · Cited by 111
Development and Characterization of a Wee1 Kinase Degrader
Li, Z., Pinch, B. J., Olson, C. M., Donovan, K. A., Nowak, R. P., Mills, C. E., Scott, D. A., Doctor, Z. M., Eleuteri, N. A., Chung, M., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.10.013 · Cited by 111
Wei, M., Zhao, R., Cao, Y., Wei, Y., Li, M., Dong, Z., Liu, Y., Ruan, H., Li, Y., Cao, S., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112903 · Cited by 111
Ying, M., Shao, X., Jing, H., Liu, Y., Qi, X., Cao, J., Chen, Y., Xiang, S., Song, H., Hu, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813139 · Cited by 108
CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance
Liu, R., Fan, M., Candas, D., Qin, L., Zhang, X., Eldridge, A., Zou, J. X., Zhang, T., Juma, S., Jin, C., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0017 · Cited by 105
Lai, A. Y., Sorrentino, J. A., Dragnev, K. H., Weiss, J., Owonikoko, T. K., Rytlewski, J. A., Hood, J. V. W., Zhao, Y., Malik, R. K., Strum, J. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000847 · Cited by 105
De Dominici, M., Porazzi, P., Xiao, Y., Chao, A., Tang, H.-Y., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L. F., et al. (2020) · Blood · doi:10.1182/blood.2019003604 · Cited by 94
Nasmyth, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00604-3 · Cited by 93
NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor
Bury, M., Calvé, B. L., Lessard, F., Maso, T. D., Saliba, J., Michiels, C., Ferbeyre, G., & Blank, V. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.087 · Cited by 92
Development of CDK2 and CDK5 Dual Degrader TMX‐2172
Teng, M., Jiang, J., He, Z., Kwiatkowski, N. P., Donovan, K. A., Mills, C. E., Victor, C., Hatcher, J. M., Fischer, E. S., Sorger, P. K., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004087 · Cited by 89
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
Li, Z., Zou, W., Zhang, J., Zhang, Y., Xu, Q., Li, S., & Chen, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580251 · Cited by 81
Cell Cycle Regulation Meets Tumor Immunosuppression
Li, J., & Stanger, B. Z. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.07.010 · Cited by 75
A novel strategy to block mitotic progression for targeted therapy
Chi, J. J., Li, H., Zhou, Z., Izquierdo-Ferrer, J., Xue, Y., Wavelet, C. M., Schiltz, G. E., Zhang, B., Cristofanilli, M., Lu, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.013 · Cited by 73
Cyclin D1 Represses Gluconeogenesis via Inhibition of the Transcriptional Coactivator PGC1α
Bhalla, K., Liu, W.-J., Thompson, K. N., Anders, L., Devarakonda, S., Dewi, R. E., Buckley, S., Hwang, B., Polster, B. M., Dorsey, S. G., et al. (2014) · Diabetes · doi:10.2337/db13-1283 · Cited by 66
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
Galvani, E., Mundra, P. A., Valpione, S., García-Martínez, P. L., Smith, M., Greenall, J., Thakur, R., Helmink, B. A., Andrews, M. C., Boon, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14632-2 · Cited by 46
Targeting SCF E3 Ligases for Cancer Therapies
Liu, J., Peng, Y., Zhang, J., Long, J., Liu, J., & Wei, W. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_9 · Cited by 42
Self-citationCyclin D1 targets hexokinase 2 to control aerobic glycolysis in myeloma cells
Caillot, M., Bourgeais, J., Dakik, H., Costé, É., Mazure, N. M., Lelièvre, E., Coqueret, O., Hérault, O., Mazurier, F., & Sola, B. (2020) · Oncogenesis · doi:10.1038/s41389-020-00253-3 · Cited by 36
Kamarajugadda, S., Becker, J. R., Hanse, E. A., Mashek, D. G., Mashek, M. T., Hendrickson, A. M., Mullany, L. K., & Albrecht, J. H. (2016) · Oncotarget · doi:10.18632/oncotarget.10274 · Cited by 33
APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation
Wu, Q., Zhang, W., Xue, L., Wang, Y., Fu, M., Ma, L., Song, Y., & Zhan, Q.-M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2341 · Cited by 22
Cited by
RNA modifications: importance in immune cell biology and related diseases
Cui, L., Ma, R., Cai, J., Guo, C., Chen, Z., Yao, L., Wang, Y., Fan, R., Wang, X., & Shi, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01175-9 · Cited by 405
Pathological implication of protein post-translational modifications in cancer
Pan, S., & Chen, R. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101097 · Cited by 263
Ye, Q., Zhou, X., Ren, H., Han, F., Lin, R., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274336 · Cited by 15
Metadata
- Authors
- Liu, J., Peng, Y., & Wei, W.
- Venue
- Trends in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 32
- Issue
- 1
- Pages
- 30-44
- ISSN
- 0962-8924 (ISSN-L)
- OpenAlex
- W3184439942
- Cited by
- 372
- References
- 103
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.